Digbi News · Oct 27, 2026
Members on tirzepatide lost 18.4% of body weight at 12 months, matching pivotal-trial results and exceeding large real-world cohorts of patients on the drug plus one-size-fits-all care.
Oct 15, 2026
More than 300 employers and health plans now offer a unified platform for metabolic, inflammatory, and hormonal care, built on each member’s gut microbiome, genetics, and glucose data, as a fully covered benefit
Oct 05, 2026
Combining Gut microbiome, genetic, and glucose signals delivers unprecedented personalized care to bring clinically meaningful relief to more than half of symptomatic members
In the news · Business Insider (via GLOBE NEWSWIRE) · Oct 05, 2026
Business Insider's markets site carried Digbi Health's release on a real-world study of nearly 16,000 members of its precision biology program, which tailors nutrition and lifestyle care to each person's gut microbiome, genetics and glucose response. After correcting for regression to the mean, the bias that flatters most single-arm digital health studies, members' IBS symptom scores fell by close to 48 points at 12 weeks, and more than half of symptomatic members crossed the 50-point threshold for clinically meaningful relief. The response grew with severity, and it held across age, sex, income and ethnicity subgroups and against medication use and the start of GLP-1 therapy. Improvement tracked the nutrient density of members' meals, not their weight change, which points to food quality matched to biology rather than weight loss as the lever for gut symptoms. For employers and health plans, the study puts real-world evidence behind GI care delivered inside a single program that also covers metabolic, inflammatory and hormonal conditions through one care team. The analysis is a preprint on medRxiv and has not yet been peer reviewed.
Oct 02, 2026
Employers can now deliver GLP-1 and hormone replacement therapy through a unified care team, without layering on another standalone point solution
In the news · The Healthcare Technology Report · Jul 01, 2026
The Healthcare Technology Report named Digbi Health to the first volume of its Top Healthcare Technology Companies of 2026, listing it in the Digital Health category. The editors built the list around companies that remove specific points of friction in care delivery rather than around size or brand recognition, and placed Digbi among awardees working in diagnostics, AI software and medical technology. The feature centers on a problem employers know well: members with overlapping chronic conditions, such as obesity, diabetes, digestive and inflammatory disorders, who are usually enrolled in a separate program for each. Digbi reads each member's genetics, gut microbiome, glucose response and blood biomarkers, then uses AI and clinician-guided care to turn that profile into a single plan spanning food, medication and coaching. The publication also highlights GLP Compass, Digbi's GLP-1 program, which uses biological data to anticipate how a member will respond to the drugs, which side effects to expect, and when tapering may be appropriate. For employers and health plans, the recognition adds independent weight to the case for consolidating point solutions into one biology-led platform, at a moment when GLP-1 spending is forcing benefits leaders to ask which members will actually benefit from the medication.
Mar 17, 2026
A new digital card platform offers a unified alternative to fragmented manufacturer programs, giving employers control over the budget, behavior and biology of obesity care.
Jan 15, 2026
Actuarial claims analysis across seven self-insured employers confirms up to 9X ROI, demonstrating the power of gut microbiome and genetics-based care.
Dec 01, 2025
A state public health insurance trust has selected Digbi Health to manage obesity treatment costs for its municipal and teachers union workers amid rising GLP-1 drug expenses.
Nov 18, 2025
The first precision biology-based telehealth service designed to improve GLP-1 tolerability, safety and effectiveness is now available as a self-pay option within employer populations.
Digbi News · Jul 27, 2025
Recognized for ten consecutive quarters by the leading marketplace employers and consultants use to find providers in the wellbeing and benefits sector.
Jan 17, 2025
GLP Compass now incorporates gut microbiome and genetic biomarkers that determine the tolerability and efficacy of GLP-1 drugs.
Oct 03, 2024
The study demonstrates how altering the gut microbiome can increase the body's natural GLP-1 production — reducing medication dosage, improving adherence and lowering costs.
Sep 24, 2024
The program combines genetic insights, gut microbiome analysis and continuous glucose monitoring to improve GLP-1 outcomes and support successful medication tapering.
In the news · Blue Shield of California · Jul 09, 2024
Blue Shield of California marked the fifth anniversary of Wellvolution, its digital health platform, naming Digbi Health among the partners delivering personalized treatment for obesity, cardiometabolic conditions and gut health using genetics and gut microbiome profiling. Digbi Health has been available to eligible Blue Shield members through Wellvolution since 2019.
Mar 15, 2024
The Houston-area blood provider will integrate genetics and gut microbiome-based personalized care into its employee wellness program.
Sep 28, 2023
The program identifies an individual's best obesity treatment path with 87% accuracy — precision nutrition alone, nutrition with lower-cost medication, or nutrition with GLP-1 therapy.
In the news · LG NOVA · Sep 07, 2022
LG NOVA, the North American Innovation Center for LG Electronics, named Digbi Health among the ten finalists of its inaugural Mission for the Future global challenge, selected from roughly 1,300 applicants. Finalists worked with LG NOVA's Entrepreneur-In-Residence team over six to nine months to build and test their proposals, and were presented to LG Electronics global CEO William Cho. Selected companies collaborate with LG NOVA on new business ventures and qualify for potential investment from LG and others in its ecosystem. Digbi Health was chosen in the digital health track, alongside companies working in electric mobility and the metaverse. LG NOVA's announcement describes Digbi as a digital care platform preventing and reversing chronic metabolic, digestive and mental health conditions using gut microbiome insight, genetics, AI and food-as-medicine, and states that LG and Digbi would work together to make care globally accessible at home and in the office.
Aug 22, 2022
The pilot will examine whether multiomic and lifestyle data can predict whether a person is at high or low risk of obesity, based on Digbi's user population.
In the news · Virgin Pulse · Jul 13, 2022
Virgin Pulse added Digbi Health to its partner ecosystem for digestive health, giving clients integrated access to more than 70 specialty solutions.
Jan 17, 2022
Care is personalized using the member's ethnic ancestry as measured by their DNA sequence, gut microbiome, food habits and food preferences.
In the news · BioSpace (via PR Newswire) · Jan 17, 2022
BioSpace carried Digbi Health's January 2022 announcement that it had built ancestry-specific genetic risk scores into its care program, covering nutrition, fitness, obesity, diabetes, hypertension and digestive health. The release argued that most genetic research draws on people of European descent, so risk models and digital care guidelines built on it serve women and people of color poorly. Digbi's scores read each member's ancestry from their DNA, alongside gut microbiome data and food habits, to personalize care, and the company pointed to a peer-reviewed study showing its program worked equally well across ethnicities and income levels.
Jul 05, 2021
Dr. Daniel Almonacid joins as Chief Scientific Officer and Dr. Parambir S. Dulai as Medical Director, Digestive and Mental Health.
Jun 16, 2021
A precision care program to improve, reverse and monitor gastrointestinal and functional bowel disorders affecting 70 million Americans, by prescribing food and lifestyle as medicine.
Mar 18, 2021
Accel led the round, with participation from Wisdom LLP and seed backers Ocean Azul Partners and Seraph Venture, bringing total funding to $8.5 million.
Jan 26, 2021
The genetics and gut microbiome-based obesity management program is covered by insurance for qualifying members, on the plan's Wellvolution platform.
Dec 22, 2020
The clinical pilot will evaluate Digbi Health's personalized obesity program in bariatric surgery patients one year after sleeve gastrectomy.
In the news · Impact RTO Holdings · Sep 10, 2020
Impact RTO Holdings, one of the largest Rent-A-Center franchisees, announced a partnership making Digbi Health's genetics and gut microbiome-based care program available to employees and their families across its store network.
Jun 29, 2020
Employees from more than 50 California government agencies have enrolled, with 70 percent reducing weight and obesity-related health risks.
Jan 23, 2020
The appointment advances Digbi's integration of genetics and microbiome science with conventional care protocols, and a more integrated role with health plans and health systems.
Nov 25, 2019
Access to personalized, clinically validated digital therapeutics for obesity and diabetes, delivered through the health plan's Solera-powered wellness navigation platform.
Newswire by Digbi is Digbi Health's own newsroom. Releases published here are issued directly by Digbi Health and are not distributed by, or affiliated with, any third-party wire service.